DK0458551T3 - Spiro-isoquinolin-pyrrolidiner og analoge deraf, som er anvendelige som aldosereduktase-inhibitorer. - Google Patents

Spiro-isoquinolin-pyrrolidiner og analoge deraf, som er anvendelige som aldosereduktase-inhibitorer.

Info

Publication number
DK0458551T3
DK0458551T3 DK91304487T DK91304487T DK0458551T3 DK 0458551 T3 DK0458551 T3 DK 0458551T3 DK 91304487 T DK91304487 T DK 91304487T DK 91304487 T DK91304487 T DK 91304487T DK 0458551 T3 DK0458551 T3 DK 0458551T3
Authority
DK
Denmark
Prior art keywords
carbon atoms
aryl
lower alkyl
pyrrolidines
isoquinoline
Prior art date
Application number
DK91304487T
Other languages
Danish (da)
English (en)
Inventor
Michael Sotirios Malamas
Original Assignee
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Prod filed Critical American Home Prod
Application granted granted Critical
Publication of DK0458551T3 publication Critical patent/DK0458551T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK91304487T 1990-05-21 1991-05-17 Spiro-isoquinolin-pyrrolidiner og analoge deraf, som er anvendelige som aldosereduktase-inhibitorer. DK0458551T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/526,356 US5037831A (en) 1990-05-21 1990-05-21 Spiro-isoquinoline-pyrrolidines and analogs thereof useful as aldose reductase inhibitors

Publications (1)

Publication Number Publication Date
DK0458551T3 true DK0458551T3 (da) 1998-08-10

Family

ID=24097007

Family Applications (1)

Application Number Title Priority Date Filing Date
DK91304487T DK0458551T3 (da) 1990-05-21 1991-05-17 Spiro-isoquinolin-pyrrolidiner og analoge deraf, som er anvendelige som aldosereduktase-inhibitorer.

Country Status (11)

Country Link
US (1) US5037831A (fr)
EP (1) EP0458551B1 (fr)
JP (1) JP3244283B2 (fr)
AT (1) ATE160780T1 (fr)
CA (1) CA2042113C (fr)
DE (1) DE69128302T2 (fr)
DK (1) DK0458551T3 (fr)
ES (1) ES2110977T3 (fr)
GR (1) GR3026186T3 (fr)
HK (1) HK1004067A1 (fr)
SG (1) SG47773A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5106978A (en) * 1991-05-22 1992-04-21 American Home Products Corporation Process and intermediates for the preparation of spiro(isoquinoline-4(1H), 3'-pyrrolidine)-1,2', 3,5'(2H)-tetrones which are useful as aldose reductase inhibitors
US5189167A (en) * 1991-11-25 1993-02-23 American Home Products Corporation Alkylidene analogs of 1'-amino-2-[(benzothiazolyl)-methyl]spiro [isoquinoline-4(1H),3'-pyrrolidine]-1,2',3,5'(2H)-tetrones useful as aldose reductase inhibitors
US5189168A (en) * 1991-11-25 1993-02-23 American Home Products Corporation 1'-amino-2[(benzothiazolyl)methyl]spiro-[isoquinoline-4(1H),3'-pyrrolidine]-1,2'3,5'(2H)-tetrones and analogs thereof useful as aldose reductase inhibitors
CA2122916A1 (fr) * 1991-11-25 1993-06-10 Michael S. Malamas 1-amino-2-[(benzothiazolyl)methyl]spiro[isoquinoline-4(1h),3'-pyrrolidine]-1,2',3,5'(2h)-tetrones et analogues de celles-ci, utiles comme inhibiteurs
US5189044A (en) * 1992-03-20 1993-02-23 American Home Products Corporation Isoquinoline-1,3-dione acetyl carbamates useful as aldose reductase inhibitors
ES2363230T3 (es) * 1997-04-15 2011-07-27 Csir Métodos no terapéuticos para suprimir el apetito.
GB2396815B (en) * 1999-10-27 2004-09-08 Phytopharm Plc A composition comprising a pregnenone derivative and an NSAID
GB2363985B (en) * 2000-06-30 2004-09-29 Phytopharm Plc Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use
JP2004514700A (ja) 2000-11-30 2004-05-20 ファイザー・プロダクツ・インク Ｇａｂａアゴニスト及びアルドース還元酵素阻害剤の組み合わせ
US20110092566A1 (en) * 2004-11-19 2011-04-21 Srivastava Satish K Treatment of cancer with aldose reductase inhibitors
US8877717B2 (en) 2007-03-12 2014-11-04 Zadec Aps Anti-diabetic extract of rooibos
EP2848252A3 (fr) 2007-03-23 2015-06-17 The Board of Regents of the University of Texas System Inhibiteurs d'aldose-réductase pour le traitement de l'uvéite
US20090270490A1 (en) * 2008-04-24 2009-10-29 The Board Of Regents Of The University Of Texas System Methods involving aldose reductase inhibition
CN103547261A (zh) 2010-12-23 2014-01-29 德克萨斯大学系统董事会 用于治疗copd的方法
CN107286092B (zh) * 2017-05-24 2020-02-21 浙江大学 甲氧基苯甲酰胺和重氮酸酯经碳-氢官能化制备异喹啉二酮的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE47592B1 (en) * 1977-12-29 1984-05-02 Ici Ltd Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture
HU198051B (en) * 1984-10-30 1989-07-28 Pfizer Process for producing spiro square brackets open imidazolidine-4,5'(6h)-quinoline square brackets closed-2,5-dione derivatives
DE3684410D1 (de) * 1985-11-07 1992-04-23 Pfizer Heterocyclische oxophthalazinylessigsaeure.
DE3769066D1 (de) * 1986-08-28 1991-05-08 Sanwa Kagaku Kenkyusho Co Hydantoin-derivate zur behandlung von komplikationen bei diabetes.
US4927831A (en) * 1988-10-20 1990-05-22 American Home Products Spiro-isoquinoline-pyrrolidine tetrones and analogs thereof useful as aldose reductase inhibitors
AU617541B2 (en) * 1988-10-20 1991-11-28 Wyeth Spiro-isoquinoline-pyrrolidine tetrones and analogs thereof useful as aldose reductase inhibitors

Also Published As

Publication number Publication date
ATE160780T1 (de) 1997-12-15
JPH04226984A (ja) 1992-08-17
DE69128302D1 (de) 1998-01-15
CA2042113A1 (fr) 1991-11-22
ES2110977T3 (es) 1998-03-01
HK1004067A1 (en) 1998-11-13
SG47773A1 (en) 1998-04-17
EP0458551B1 (fr) 1997-12-03
JP3244283B2 (ja) 2002-01-07
DE69128302T2 (de) 1998-03-26
CA2042113C (fr) 2001-08-28
EP0458551A1 (fr) 1991-11-27
GR3026186T3 (en) 1998-05-29
US5037831A (en) 1991-08-06

Similar Documents

Publication Publication Date Title
DK0458551T3 (da) Spiro-isoquinolin-pyrrolidiner og analoge deraf, som er anvendelige som aldosereduktase-inhibitorer.
IL103825A0 (en) Aromatic amino-alcohol derivatives,a method for the preparation thereof and pharmaceutical compositions containing the same
FI893467A0 (fi) Menetelmä lääkeaineena käyttökelpoisten 4-oksokinoliini-3-karboksyylihapon johdannaisten valmistamiseksi
DK0430201T3 (fr)
HUT50337A (en) Process for producing benzoxazine derivatives and pharmaceutical compositions comprising the compounds
CA2030732A1 (fr) Nouveaux derives du thiophene, leur procede de preparation et les compositions pharmaceutiques les renfermant
CA2042112A1 (fr) N'-alkylspiro-isoquinoleinepyrrolidinetetrones et leurs analogues, utiles comme agents inhibiteurs de l'aldose-reductase
DK0410305T3 (da) Anvendelse af bis(4-hydroxyphenylthio)methanderivater til behandling af diabetes mellitus
ES8606295A1 (es) Un procedimiento para la preparacion de nuevas espiro-3-heteroazolidindionas.
NO914192L (no) 8-azabicyklo(3.2.1)oktylalkylthiazolidinoner, fremgangsmaate for fremstilling og anvendelse som medikamenter
KR930702346A (ko) 알도스 리덕타제 억제제로서 유용한 1'-아미노스피로[이소퀴놀린-4(1h),3'-피롤리딘]-1,2',3,5'(2h)-테트론 및 이의 동족체
DK0410343T3 (da) Anvendelse af bisphenolderivater til behandling af diabetes mellitus
HK108997A (en) 1'-amino-2-(benzothiazolyl)methyl¾spiro isoquinoline-4(1H),3'-pyrrolidine¾-1,2',3,5'(2H)-tetrones and analogs thereof useful as aldose reductase inhibitors
UA81596C2 (en) Nitro-sulfobenzamides
DE3879650T2 (de) N-acyl-n-naphthoylglycine als aldose-reductase-inhibitoren.
ES2032413T3 (es) Procedimiento para preparar pirimidoquinoxalinas sustituidas. (reserva del art. 167.2 cpe).